Topoisomerase - Knowledge

717:, targets human topo I and derivatives such as topotecan and irinotecan are widely used in cancer chemotherapy. Camptothecin and its derivatives act by stabilizing the topo I cleavage complex, preventing religation of the protein-mediated nick in the DNA. These interfacial inhibitors are stabilized by stacking interactions with the nicked DNA and hydrogen bonding to the enzyme. Although CPT derivatives stabilize a single-strand cleavage complex, subsequent collisions with replication or transcription machinery are thought to generate toxic double-stranded DNA breaks. These compounds are used as first or second line therapies to treat cancers including colorectal, ovarian, lung, breast, and cervical. However, CPT derivatives suffer from limitations associated with toxicity and limited therapeutic half-lives due to chemical instability. New topo I inhibitors, the indenoisoquinolines and fluoroindenoisoquinolines, overcome the limitations of CPT derivatives and are currently in clinical trials. 586:

Whereas all type II topoisomerases can catalyze DNA relaxation, gyrase, an archetypal bacterial topoisomerase, can also introduce negative supercoils. In contrast to type I topoisomerases that are generally monomeric, type II topoisomerases are homodimers or heterotetramers. They are classified into two subtypes based on evolutionary, structural, and mechanistic considerations. The general strand-passage mechanism for the type II topos begins with the binding of one DNA duplex, termed the gate segment (G-segment), at the DNA gate. Another duplex, termed the transport segment (T-segment), is captured by an ATP-operated clamp and passed through a transient break in the G-segment, involving 5ʹ phosphotyrosine linkages in both strands, before it is released through the C-gate and the G-segment is re-ligated (Fig. 5). Enzyme turnover requires the binding and hydrolysis of ATP.

398:. If left unchanged, this torsion would eventually stop the DNA or RNA polymerases involved in these processes from continuing along the DNA helix. A second topological challenge results from the linking or tangling of DNA during replication. Left unresolved, links between replicated DNA will impede cell division. The DNA topoisomerases prevent and correct these types of topological problems. They do this by binding to DNA and cutting the sugar-phosphate backbone of either one (type I topoisomerases) or both (type II topoisomerases) of the DNA strands. This transient break allows the DNA to be untangled or unwound, and, at the end of these processes, the DNA backbone is resealed. Since the overall chemical composition and connectivity of the DNA do not change, the DNA substrate and product are chemical isomers, differing only in their topology. 453: 1155: 449:

conformations of DNA, such as supercoils, knots and catenanes. Potential topological issues associated with the double-helical structure of DNA were recognized soon after its structure was first elucidated in 1953 by James Watson, Francis Crick and Rosalind Franklin and developed further by the work of Max Delbruck and John Cairns. Closed-circular double-stranded DNA can be described by 3 parameters: Linking number (Lk), Twist (Tw) and Writhe (Wr) (Fig. 1). Where Lk refers to the number of times the two strands are linked, Tw refers to the number of helical turns in the DNA, measured relative to the helical axis, and Wr quantifies the coiling of the path of the DNA helix in space and is often equated with 'supercoiling'.

618:, in addition to bacterial gyrase and topo IV. DNA gyrase conforms to the same double-strand passage mechanism as other type II enzymes but has unique features connected with its ability to introduce negative supercoils into DNA. The G segment is part of a much longer piece of DNA (>100 bp) that is wrapped around the enzyme, one arm of which forms the T-segment that is passed through the double-stranded break (Fig. 5). In the case of gyrase, a substantial amount of the free energy from ATP hydrolysis is transduced into torsional stress in DNA, i.e. supercoiling is an energy-requiring process. Further, in the absence of ATP, gyrase is able to remove negative supercoils in a slower DNA relaxation reaction. 486: 474:

recombination reactions. In general, knots in DNA are detrimental and need to be removed (by topoisomerases). DNA catenanes are formed upon the replication of circular molecules and need to be resolved by topoisomerases or recombinases to allow proper separation of daughter molecules during cell division. In addition to the detrimental aspects of DNA topology that require resolution, there are also beneficial aspects. For example, plasmid replication requires negative supercoiling of the origin, which facilitates local melting and exposes single-stranded DNA required to initiate replication. Similarly, initiation of replication from the main bacterial origin

561:'controlled rotation' of the cleaved strand around the intact strand. This controlled-rotation mechanism was first described for Vaccinia topo I and permits DNA rotation of the free end around the intact strand, the speed being controlled by 'friction' within the enzyme cavity, before the nick is re-ligated (Fig. 3). This results in a variable change of linking number per cleavage and religation event. This mechanism is distinct from that of the type IA enzymes, and the two groups of enzymes are structurally and evolutionarily unrelated. Examples of type IB topoisomerases include eukaryotic nuclear and mitochondrial topo I in addition to viral 735: 750:

and remain among the most widely employed and effective treatments for a broad range of cancers including breast cancer, lymphoma, leukemias, carcinomas, sarcomas, and other tumors. These compounds are DNA intercalating agents and as such can impact a wide range of cellular DNA processes in addition to specifically poisoning topo II. Additional cytotoxicity stems from redox reactions involving anthracyclines that generate reactive oxygen species. Generation of reactive oxygen, along with poisoning of topo IIβ, result in the dose-limiting cardiotoxicity of the anthracyclines.

658:

DNA at the cleavage site to stabilize the DNA-protein covalent cleavage intermediate. Specifically, they intercalate into the DNA and prevent the DNA religation step of the topoisomerase reaction (Fig. 5). This is a highly-effective mechanism of inhibition that is also used by several topoisomerase-targeted anti-cancer drugs. Despite their spectacular success, resistance to FQs is a serious problem. A variety of other compounds, such as quinazolinediones and imidazolpyrazinones, work in a similar manner and it is hoped that some of these will replace FQs in the future.

506: 465:

interconvertible and depend upon the solution conditions. Supercoiling is a vernacular term for DNA with a non-zero linking difference, more correctly referred to as specific linking difference (σ = ΔLk/Lk, where Lk is the mean linking number of the relaxed DNA circle). DNA is said to be positively supercoiled if Lk of it is higher than Lk for the relaxed state (Lk-Lk = ΔLk, ΔLk>0); that means that Tw and/or Wr are increased relative to the relaxed molecule. Conversely, DNA is negatively supercoiled if Lk of the molecule is lower than the Lk (ΔLk<0).

590: 545: 683: 492:. Topological consequences of DNA metabolism. i) During DNA replication, strand separation leads to positive supercoiling ahead of the advancing protein machinery, and precatenane formation behind. Precatenanes form as the newly-synthesised duplexes wrap around one and other, and, if not removed prior to complete of replication, catenated DNA molecules are formed. ii) During transcription, strand separation leads to positive supercoiling ahead of the advancing protein machinery, and negative supercoil formation behind. 532:

or G-segment, and its cleavage allows the passage of another segment of DNA, the 'transport' or T-segment, to be passed through in a 'strand-passage' process. This is followed by ligation of the G-segment. For strand passage to occur, topo IA must undergo a conformational change to open the DNA gate and allow T-segment transfer. During a DNA relaxation reaction this process changes the linking number of the DNA by +/-1 (Fig. 4). Examples of type IA topoisomerases include prokaryotic topo I and III, eukaryotic

460:

in the double helix, approximately once per 10.5 base-pairs (Tw~ 10.5). Supercoiling corresponds to increases or decreases of the linking number (∆Lk) that result from cellular processes such as DNA transcription and replication (Figure 2). Changes in linking number are accommodated by changes in twist (torsion) (Tw) and writhe (Wr), which change the structure and mechanics of DNA. Knotting within a DNA molecule and links between DNA molecules (catenanes) represent higher order topological conformations of DNA.

551:. Strand-passage mechanism for type IA topos. (1) Topo binds the G-segment ssDNA region, (2) the G-segment is cleaved. (3) The topo DNA gate is opened, (4) which allows T-segment transfer through the cleaved G-strand. (5) The DNA gate is closed, (6) and the G-strand is re-ligated, changing the linking number by 1. (7) The topo can then go through another round of relaxation or dissociate from the DNA. Type IA topo (domains 1-4) is in pink, the active site tyrosine is yellow and the DNA is grey. 596:. Type II topoisomerase strand-passage mechanism. (1) G-segment is bound at the DNA-gate and the T-segment is captured. (2) ATP binding stimulates dimerization of the N-gate, the G-segment is cleaved and the T-segment is passed through the break. (3) The G-segment is re-ligated and the T-segment exits through the C-gate. For type IIB topos, there is no C-gate so once the T-segment passes through the G-segment, it is released from the enzyme. (4) Dissociation of ADP and P 1528:

by Singh et al., "about 80% of highly expressed genes in HeLa cells are paused". Very short-term, but not immediately resealed, topo IIβ-induced DNA double-strand breaks occur at sites of RNA polymerase II pausing, and appear to be required for efficient release of the paused state and progression to gene transcription. For the genes at which it occurs, the DNA double-stranded break induced by TOP2B is thought to be part of the process of regulation of gene expression.

469:

strands (precatenanes) behind (Fig. 2). If the positive supercoils are not relaxed, progression of the replication fork is impeded, whereas failure to unlink the daughter strands prevents genome segregation, which is required for cell division. Transcription by RNA polymerase also generates positive supercoiling ahead of, and negative supercoiling behind, the transcriptional complex (Fig. 2). This effect is known as the twin-supercoiled domain model, as described by

6251: 627:

structural differences, but are evolutionarily related to the type IIA enzymes. These differences include the lack of one of the protein 'gates' (the C gate) (Fig. 5). Originally found in archaea, they have also been found in eukaryotes, and, in particular, in plants; examples include topo VI and topo VIII. Topo VI is the best-studied enzyme of this sub-type and is thought to be a preferential decatenase.

513:

5ʹ DNA phosphate and function via a strand passage mechanism. Type IB and IC form a transient covalent bond to the 3ʹ DNA phosphate and function via a controlled-rotation mechanism. Type II topoisomerases are further subdivided into type IIA and IIB. Both form a transient covalent bond to the 5ʹ DNA phosphate of both strands of the duplex and function via a strand-passage mechanism.

640:. The reason for this prominence is that their reactions proceed via transient breaks in DNA, which, if stabilized by drug binding, can lead to cell death due to the generation of toxic single- or double-stranded breaks in genomic DNA. The majority of topo-targeted drugs act in this way, i.e. they stabilize the enzyme-DNA covalent cleavage intermediate. 725:

Etoposide (Fig. 7) and its close relative teniposide (VM-26) are epipodophyllotoxin derivatives obtained from the rhizome of wild mandrake that target topo II by stabilizing the covalent cleavage complex and preventing religation of the cleaved DNA. These are typically used in conjunction with other

585:

Type II topoisomerases catalyze changes in DNA topology via transient double-stranded breaks in DNA. Reactions occur on double-stranded DNA substrates and proceed via a strand-passage mechanism (Fig. 5). The range of reactions include DNA relaxation, DNA supercoiling, unknotting, and decatenation.

1527:

RNA polymerase II frequently has a pausing site that is about 30–60 nucleotides downstream of the transcription start site of a gene. The pausing of RNA polymerase II at these sites and the controlled release of the pausing is thought to have a regulatory role in gene transcription. As pointed out

657:

Quinolone antibacterial compounds were first developed in the 1960s and have been in clinical use since the 1980s. FQ derivatives, such as ciprofloxacin, levofloxacin and moxifloxacin (Fig. 6) have been highly-successful. These compounds work by interacting with their target (gyrase or topo IV) and

648:

Although type I topos, such as bacterial topo I, are viable antibiotic targets, there are currently no compounds in clinical use that target these enzymes. However, the type II enzymes, DNA gyrase and DNA topoisomerase IV, have enjoyed enormous success as targets for the widely-used fluoroquinolone

626:

Type IIB also catalyze transient double-stranded breaks through the formation of tyrosyl-phosphate bonds between tyrosines in the enzyme and 5′-phosphates in opposite strands of the DNA, but in the case of IIB enzymes the double-stranded breaks have a 2-base stagger. Type IIB enzymes show important

609:

Type IIA topoisomerases catalyze transient double-stranded breaks in DNA through the formation of tyrosyl-phosphate bonds between tyrosines in the enzyme (one on each subunit) and 5′-phosphates staggered by 4 bases in opposite DNA strands. The strand-passage reaction can be intra- or intermolecular

531:

Type IA are monomeric and bind to single-stranded segments of DNA. They introduce a transient single-stranded break through the formation of a tyrosyl-phosphate bond between a tyrosine in the enzyme and a 5′-phosphate in the DNA. The segment of DNA within which the break occurs is called the 'gate'

512:

Summary of topoisomerase types and catalytic mechanisms. The topoisomerases are categorized based on whether they catalyze single- (type I) or double-stranded (type II) DNA breaks. The type I topoisomerases are further subdivided to type IA, IB and IC. Type IA form a transient covalent bond to the

468:

The consequences of topological perturbations in DNA are exemplified by DNA replication during which the strands of the duplex are separated; this separation leads to the formation of positive supercoils (DNA overwinding or overtwisting) ahead of the replication fork and intertwining of the daughter

459:

Overview of DNA topology. The linking number (Lk) describes the number of times that the two single-strands of DNA cross each other in a closed circular DNA molecule. Relaxed DNA molecules have an intrinsic linking number (Lk) corresponding to the twisting of the two single-strands around each other

749:

that target human topo II, stabilizing the cleavage complex in a similar manner to other topoisomerase poisons. Mitoxantrone is a synthetic anthracenedione that is chemically and functionally similar to anthracyclines. The anthracyclines were the first topoisomerase inhibitors used to treat cancer

1186:

DNA repair pathway, including DNA-PKcs, Ku70/Ku80 and DNA ligase IV assembled with topo IIβ and PARP-1. This assemblage was all present at the linker DNA adjacent to a single nucleosome in the promoter region of a gene (see Figure). The nucleosome was close to the transcription start site of the

1134:

Stimulus-induced DNA double-strand breaks (DSBs) that are limited to a short-term (10 minutes to 2 hours) are induced by topo IIβ in the promoter regions of signal-regulated genes. These DSBs allow rapid up-regulation of expression of such signal responsive genes in a number of systems (see Table

758:

Merbarone is a thiobarbituric acid derivative, and dexrazoxane (ICRF-187), one of several related bisdioxopiperazine derivatives, (Fig. 7) are examples of catalytic inhibitors of topo II, i.e. they prevent completion of the catalytic cycle of topo II but do not stabilize the DNA cleavage complex.

540:

and the archaeal enzyme reverse gyrase. Reverse gyrase, which occurs in thermophilic archaea, comprises a type IA topo coupled to a helicase, and is the only known enzyme that can introduce positive supercoils into DNA. The gene encoding reverse gyrase is also found in some groups of thermophilic

448:

The double-helical structure of DNA involves the intertwining of the two polynucleotide strands around each other, which potentially gives rise to topological problems. DNA topology refers to the crossing of the two DNA strands that alters the twist of the double helix and gives rise to tertiary

853:

Removes (-), but not (+) supercoils; assists in the unlinking of precatenanes in cellular DNA replication; can catalyze the knotting, unknotting, and interlinking of single-stranded circles as well as the knotting, unknotting, catenation, and decatenation of gapped or nicked duplex DNA circles

698:

Both human topo I and topo II (both α and β isoforms) can be targeted in anticancer chemotherapy (Fig. 7). Most of these compounds act in a similar way to FQs, i.e. by stabilizing the DNA-protein covalent cleavage complex; for this they have become known as topoisomerase poisons, distinct from

560:

Type IB topoisomerases catalyze reactions involving transient single-stranded breaks in DNA through the formation of a tyrosyl-phosphate bond between a tyrosine in the enzyme and a 3′-phosphate in the DNA. Rather than utilizing a strand-passage mechanism, these enzymes operate via a 'swivel' or

501:

DNA topoisomerases are enzymes that have evolved to resolve topological problems in DNA (Table 2). They do this via transient breakage of one or both strands of DNA. This has led to the classification of topos into two types: type I, which catalyze reactions involving transient single-stranded

522:

These enzymes catalyze changes in DNA topology via transient single-stranded breaks in DNA. Reactions can occur on both single- and double-stranded DNA substrates and can proceed via a 'swivel' or 'strand-passage' mechanism (Fig. 3). The range of reactions includes: DNA supercoil relaxation,

464:

The 3 parameters are related as follows: Lk = Tw +Wr. This is a mathematical identity originally obtained by Călugăreanu in 1959 and is referred to as the Călugăreanu, or Călugăreanu–White–Fuller, theorem. Lk cannot be altered without breaking one or both strands of the helix; Tw and Wr are

679:

antibacterial compounds. Other protein inhibitors of gyrase prevent DNA binding by the topoisomerase rather than stabilizing cleavage complexes. These include YacG and pentapeptide repeat proteins, such as QnrB1 and MfpA; these protein inhibitors also confer resistance to fluoroquinolones.

678:

There are a number of protein inhibitors of gyrase, including the bacterial toxins CcdB, MccB17, and ParE, that stabilize the cleavage complex, in a similar manner to FQs. Although these proteins are not viable as antibacterials, their mode of action could inspire the development of novel

473:

and James Wang in 1987. These topological perturbations must be resolved for DNA metabolism to proceed, allowing the cell to efficiently replicate, transcribe and partition the genome to enable cellular division and vitality. Knots in DNA can be found in bacteriophages and as products of

426:

from bacteria, by Martin Gellert and coworkers in 1976, and also characterized by Nicholas Cozzarelli and co-workers. DNA gyrase catalyzes the introduction of negative supercoils into DNA and is the only type II enzyme to do this, all the others catalyze DNA relaxation. Type II enzymes are

390:, interconverting relaxed and supercoiled forms, linked (catenated) and unlinked species, and knotted and unknotted DNA. Topological issues in DNA arise due to the intertwined nature of its double-helical structure, which, for example, can lead to overwinding of the DNA duplex during DNA 759:

Whereas these catalytic inhibitors exhibit cytotoxicity and have been tested in clinical trials, they are not currently in clinical use for cancer therapy. However, dexrazoxane, which blocks ATP hydrolysis by topo II, is used to prevent cardiotoxicity associated with the anthracyclines.

635:

For the non-specialist perhaps the most important aspect of topoisomerases is their role as drug targets both for antibacterial and anti-cancer chemotherapy; several topoisomerase-targeted antibacterial and anti-cancer drugs are listed among the 2019 World Health Organization

670:, are natural products from Streptomyces that inhibit the ATPase reaction of gyrase and topo IV. Although they can be very potent against their target, they suffer from permeability and toxicity issues, and thus have not enjoyed the level of clinical success of the FQs. 427:

mechanistically distinct from type I in being ATP-dependent and transiently cleaving both DNA strands rather than just one. Type II topoisomerases were subsequently identified from bacterial viruses and eukaryotes. Topo EC-codes are as follows: ATP-independent (type I),

1169:

Topo IIβ and PARP-1 were found to be constitutively present at a moderate level near the transcription start site of a promoter of a signal-responsive gene. After the signal occurred, topo IIβ caused a double-strand break and PARP-1 was involved in replacing

1121:

At least one topoisomerase, DNA topoisomerase II beta (topo IIβ), has a regulatory role in gene transcription. Topo IIβ–dependent double-strand DNA breaks and components of the DNA damage repair machinery are important for rapid expression of

435:

5.6.2.2. The exception among the type I topoisomerases, reverse gyrase, which contains a helicase domain (EC 3.6.4.12) and introduces positive supercoiling in an ATP-dependent manner. Therefore it is the sole type I topoisomerase classified as

726:

chemotherapy drugs to treat cancers including testicular tumors, small-cell lung cancer, and leukemia. Etoposide treatment can result in secondary leukemias arising from specific genomic translocations, mainly involving topo IIβ.

3991:

Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, et al. (September 1988). "Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer".

523:

unknotting of single-stranded circles, and decatenation, provided at least one partner has a single-stranded region. In the case of the archaeal enzyme, reverse gyrase, positive supercoiling of DNA is possible.

610:(Fig. 5), thus permitting changes in supercoiling and knotting, or unlinking, respectively. This process changes the linking number of the DNA by +/-2. Examples of type IIA topoisomerases include eukaryotic 4276:

Dellino GI, Palluzzi F, Chiariello AM, Piccioni R, Bianco S, Furia L, De Conti G, Bouwman BA, Melloni G, Guido D, Giacò L, Luzi L, Cittaro D, Faretta M, Nicodemi M, Crosetto N, Pelicci PG (June 2019).

1126:, as well as for signal-responsive gene regulation. Topo IIβ, with other associated enzymes, appears to be important for the release of paused RNA polymerase at highly transcribed or long genes. 422:

and Renato Dulbecco; the enzyme responsible, eukaryotic topo I, has a distinct mechanism and is representative of the type IB family. The first type II topoisomerase to be discovered was

2529:

Sundin O, Varshavsky A (September 1981). "Arrest of segregation leads to accumulation of highly intertwined catenated dimers: dissection of the final stages of SV40 DNA replication".

4222:

Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG (June 2006). "A topoisomerase II beta-mediated dsDNA break required for regulated transcription".

4439:

Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG (June 2006). "A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription".

2779:

Liu LF, Liu CC, Alberts BM (March 1980). "Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break".

1909:

Baldi MI, Benedetti P, Mattoccia E, Tocchini-Valentini GP (June 1980). "In vitro catenation and decatenation of DNA and a novel eucaryotic ATP-dependent topoisomerase".

1151:) and activation of neurons. When the induced DNA double-strand break has been repaired, then transcription of the signal-responsive gene returns to a low basal level. 600:

allows N-gate opening, a scenario where the enzyme either remains bound to the G-segment, ready to capture a successive T-segment, or (5) dissociates from the G-segment.

573:

Type IC topoisomerases share a similar mechanism to the type IB enzymes but are structurally distinct. The sole representative is topo V, found in the hyperthermophile

1742:"An activity from mammalian cells that untwists superhelical DNA--a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay)" 343: 172: 418:) topoisomerase I (topo I) and is a representative of the type IA family of enzymes. Subsequently, a similar activity was found in eukaryotic cells (rat liver) by 1852:"Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme" 2919:

Stivers JT, Harris TK, Mildvan AS (April 1997). "Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation".

1952:

Liu LF, Liu CC, Alberts BM (October 1979). "T4 DNA topoisomerase: a new ATP-dependent enzyme essential for initiation of T4 bacteriophage DNA replication".

6026: 2824:"Widespread distribution of archaeal reverse gyrase in thermophilic bacteria suggests a complex history of vertical inheritance and lateral gene transfers" 502:

breaks, and type II, which catalyze reactions involving transient double-stranded breaks (Fig. 3; Table 2). Sub-types exist within these classifications.

5189: 1191:

Agents causing temporary DNA double-strand breaks (DSBs) required for transcription and proteins associated with the DSBs in signal-responsive genes.

1388: 1392: 362: 191: 1467: 1407: 1292: 1243: 3712:"Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide" 1187:

gene. The components of the non-homologous end joining DNA repair pathway were essential to the closing of the DNA double-strand break.

745:

Doxorubicin (Fig. 7) and the related derivatives daunorubicin, epirubicin, and idarubicin are anthracyclines obtained from the bacterium

5247: 1165:

DNA repair pathway components DNA-PKcs, Ku70/Ku80 and DNA ligase are also closely associated with the topo IIβ dimer-PARP-1 complex.

5163: 4278:"Release of paused RNA polymerase II at specific loci favors DNA double-strand-break formation and promotes cancer translocations" 4118:

Bunch H, Jeong J, Kang K, Jo DS, Cong AT, Kim D, Kim D, Cho DH, Lee YM, Chen BP, Schellenberg MJ, Calderwood SK (October 2021).

2005:"T4 DNA-delay proteins, required for specific DNA replication, form a complex that has ATP-dependent DNA topoisomerase activity" 355: 184: 6001: 5811: 5774: 5352: 1182:, which can promote transcription. Topo IIβ and PARP-1 increased at the site of the double-strand break and components of the 4824: 3786: 3382: 2078: 1601:"DNA topoisomerases: Advances in understanding of cellular roles and multi-protein complexes via structure-function analysis" 700: 5746: 322: 151: 4027:

Cvetković RS, Scott LJ (2005). "Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy".

3506:"A strand-passage conformation of DNA gyrase is required to allow the bacterial toxin, CcdB, to access its binding site" 2204:

Franklin RE, Gosling RG (July 1953). "Evidence for 2-chain helix in crystalline structure of sodium deoxyribonucleate".

5894: 2876:

Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ (March 1998). "A model for the mechanism of human topoisomerase I".

5903: 5469: 4872: 3888: 3373:

Maxwell A, Bush NG, Germe T, McKie SJ (2018). "Non-quinolone topoisomerase inhibitors". In Fong IW, Drlica K (eds.).

17: 5617: 5285: 2153:

Watson JD, Crick FH (April 1953). "Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid".

1053:

Essential; Unlinks intertwined daughter duplexes in replication; contributes to DNA relaxation during transcription

6183: 5956: 2728:

Kikuchi A, Asai K (1984). "Reverse gyrase--a topoisomerase which introduces positive superhelical turns into DNA".

485: 5816: 3871:

Murphy MB, Mercer SL, Deweese JE (January 2017). "Inhibitors and Poisons of Mammalian Type II Topoisomerases".

809:

Removes (-), but not (+) supercoils. Prevents excessive supercoiling of the genome, and supports transcription

316: 298: 145: 127: 6054: 5626: 5476: 5240: 5028: 4390:"Pausing sites of RNA polymerase II on actively transcribed genes are enriched in DNA double-stranded breaks" 1448: 5939: 4598:"Glucocorticoid Receptor Transcriptional Activation via the BRG1-Dependent Recruitment of TOP2β and Ku70/86" 2255:

Cairns J (March 1963). "The bacterial chromosome and its manner of replication as seen by autoradiography".

303: 132: 5273: 5156: 5260: 3604:"The pentapeptide-repeat protein, MfpA, interacts with mycobacterial DNA gyrase as a DNA T-segment mimic" 5605: 5225: 3005:"The ancestral role of ATP hydrolysis in type II topoisomerases: prevention of DNA double-strand breaks" 367: 196: 6241: 6031: 5994: 5722: 5591: 5423: 5370: 5264: 3769:

Pommier Y, Tanizawa A, Kohn KW (1994). "Mechanisms of topoisomerase I inhibition by anticancer drugs".

1183: 1162: 291: 120: 4539:

Bunch H, Lawney BP, Lin YF, Asaithamby A, Murshid A, Wang YE, Chen BP, Calderwood SK (December 2015).

55: 5800: 5129: 5116: 5103: 5090: 5077: 5064: 5051: 5013: 2633:"The Stringent Response Inhibits DNA Replication Initiation in E. coli by Modulating Supercoiling of 3661:

Mazurek Ł, Ghilarov D, Michalczyk E, Pakosz Z, Metelev M, Czyszczoń W, et al. (February 2021).

2102:

Watson JD, Crick FH (May 1953). "Genetical implications of the structure of deoxyribonucleic acid".

1161:

The 5' ends of DNA are covalently joined to tyrosine within the topo IIβ dimer-PARP-1 complex. The

6276: 5961: 5233: 5180: 5023: 4977: 4920: 4844: 3907:

Hande KR (October 1998). "Clinical applications of anticancer drugs targeted to topoisomerase II".

3663:"Pentapeptide repeat protein QnrB1 requires ATP hydrolysis to rejuvenate poisoned gyrase complexes" 3457:"ParE toxin encoded by the broad-host-range plasmid RK2 is an inhibitor of Escherichia coli gyrase" 1656:

Sutormin DA, Galivondzhyan AK, Polkhovskiy AV, Kamalyan SO, Severinov KV, Dubiley SA (2021-03-15).

437: 432: 428: 221: 38: 734: 637: 319: 148: 6059: 5363: 5294: 5149: 4925: 3555:"Direct control of type IIA topoisomerase activity by a chromosomally encoded regulatory protein" 1154: 395: 243: 72: 6036: 5860: 5791: 4647:"Profiling DNA break sites and transcriptional changes in response to contextual fear learning" 3553:

Vos SM, Lyubimov AY, Hershey DM, Schoeffler AJ, Sengupta S, Nagaraja V, Berger JM (July 2014).

1135:

below). These signal-regulated genes include genes activated in response to stimulation with

4840: 6218: 5987: 5786: 5555: 5202: 4946: 4865: 3408:"The Microbial Toxin Microcin B17: Prospects for the Development of New Antibacterial Agents" 1552: 1312: 910:

Removes (+) and (-) supercoils; supports fork movement during replication and transcription

713: 3944:"The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives" 1577: 1572: 537: 533: 5833: 5806: 5757: 5197: 5018: 4766: 4658: 4552: 4448: 4339: 4231: 3723: 3615: 2885: 2737: 2585: 2483: 2381: 2303: 2213: 2162: 2111: 2016: 1961: 1863: 1804: 1547: 1452: 1123: 689:. Structures of antibiotic compounds that target bacterial DNA gyrase and topoisomerase IV. 1705:

Wang JC (February 1971). "Interaction between DNA and an Escherichia coli protein omega".

1567: 1562: 615: 611: 279: 108: 8: 5563: 4982: 2686:"The level of supercoiling affects the regulation of DNA replication in Escherichia coli" 1277: 505: 50: 4770: 4662: 4556: 4452: 4388:

Singh S, Szlachta K, Manukyan A, Raimer HM, Dinda M, Bekiranov S, Wang YH (March 2020).

4343: 4235: 3727: 3619: 3602:

Feng L, Mundy JE, Stevenson CE, Mitchenall LA, Lawson DM, Mi K, Maxwell A (March 2021).

2889: 2741: 2589: 2487: 2385: 2307: 2217: 2166: 2115: 2020: 1965: 1867: 1808: 589: 255: 84: 6271: 6157: 4915: 4789: 4754: 4730: 4705: 4681: 4646: 4622: 4597: 4573: 4540: 4516: 4491: 4472: 4416: 4389: 4360: 4327: 4305: 4255: 4199: 4144: 4119: 4095: 4070: 3968: 3943: 3880: 3841: 3816: 3687: 3662: 3638: 3603: 3579: 3554: 3530: 3505: 3486: 3432: 3407: 3347: 3320: 3293: 3268: 3244: 3219: 3192: 3167: 3132: 3107: 3080: 3053: 3029: 3004: 2980: 2955: 2850: 2823: 2804: 2761: 2661: 2632: 2554: 2452: 2237: 2186: 2135: 1985: 1934: 1682: 1657: 1638: 1625: 1600: 1496:

Fear conditioning (evaluated in mouse hippocampal and medial prefontal cortex neurons)

1159:

Paused RNA polymerase and limited, short-term topo IIβ-induced DNA double-strand break.

1092:

Relaxes (+) and (-) supercoils; responsible for decatenating replication intermediates

544: 226: 43: 4817:

Untangling the Double Helix: DNA entanglement and the action of the DNA topoisomerases

3920: 3778: 3746: 3711: 3269:"Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics" 2792: 2608: 2573: 2404: 2369: 2349:

Călugăreanu G (1959). "L'intégrale de Gauss et l'analyse des nœuds tridimensionnels".

2326: 2291: 2268: 2039: 2004: 1886: 1851: 1827: 1792: 1768: 1741: 5769: 5586: 5141: 4820: 4794: 4735: 4686: 4627: 4578: 4521: 4476: 4464: 4421: 4365: 4328:"A nucleotide resolution map of Top2-linked DNA breaks in the yeast and human genome" 4309: 4297: 4259: 4247: 4203: 4191: 4149: 4100: 4044: 4040: 4009: 3973: 3924: 3884: 3846: 3792: 3782: 3751: 3692: 3643: 3584: 3535: 3478: 3473: 3456: 3437: 3388: 3378: 3352: 3298: 3249: 3197: 3137: 3085: 3034: 2985: 2936: 2901: 2855: 2796: 2753: 2707: 2702: 2685: 2666: 2613: 2546: 2542: 2511: 2506: 2471: 2444: 2409: 2331: 2272: 2229: 2178: 2127: 2084: 2074: 2044: 1977: 1926: 1922: 1891: 1832: 1773: 1722: 1718: 1687: 1642: 1630: 310: 139: 3490: 2558: 1938: 541:

bacteria, where it was likely transferred by horizontal gene transfer from Archaea.

6193: 6046: 5726: 5575: 5570: 5462: 5212: 4961: 4956: 4930: 4858: 4784: 4774: 4725: 4717: 4676: 4666: 4617: 4609: 4568: 4560: 4511: 4503: 4456: 4411: 4401: 4355: 4347: 4289: 4277: 4239: 4183: 4139: 4131: 4090: 4082: 4036: 4001: 3963: 3955: 3916: 3876: 3836: 3828: 3774: 3741: 3731: 3682: 3674: 3633: 3623: 3574: 3566: 3525: 3517: 3468: 3427: 3419: 3342: 3332: 3321:"Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance" 3288: 3280: 3239: 3231: 3187: 3183: 3179: 3127: 3119: 3075: 3065: 3024: 3016: 2975: 2967: 2928: 2893: 2845: 2835: 2808: 2788: 2765: 2745: 2697: 2656: 2648: 2603: 2593: 2538: 2501: 2491: 2436: 2399: 2389: 2321: 2311: 2264: 2241: 2221: 2190: 2170: 2139: 2119: 2034: 2024: 1989: 1969: 1918: 1881: 1871: 1822: 1812: 1763: 1753: 1714: 1677: 1669: 1620: 1612: 1384: 1228: 1021: 4326:

Gittens WH, Johnson DJ, Allison RM, Cooper TJ, Thomas H, Neale MJ (October 2019).

3959: 2897: 682: 6167: 6162: 6152: 6147: 6142: 6137: 6132: 6127: 5731: 5323: 5256: 5008: 4992: 4905: 4671: 1557: 699:

catalytic inhibitors. Several human topoisomerase inhibitors are included on the

562: 391: 4005: 3832: 3817:"Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors" 836:

Removes (-), but not (+) supercoils; overlapping function with topoisomerase IV

6255: 6117: 6112: 6107: 6102: 6097: 6092: 6087: 6082: 6077: 5579: 5559: 5046: 4987: 4507: 4351: 3716: